2025年全球医药行业收购活动活跃，又一家跨国药企发起“补强型并购“！

制药网07-18

【制药网行业动态】近日，美国天境生物(I-Mab，NASDAQ：IMAB)宣布达成最终协议，通过全资收购Bridge Health Biotech公司，进一步巩固其在肿瘤免疫治疗领域特别是CLDN18.2靶点上的竞争优势。根据协议条款，天境生物将向Bridge Health股东支付180万美元的首付款，并在2027年前完成总计120万美元的非或有付款(assured payments)。此外，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2552456377?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-18 11:08","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2552456377","market":"us","top_or_hot":-1,"title":"2025年全球医药行业收购活动活跃，又一家跨国药企发起“补强型并购“！","media":"制药网","content":"<div>\n<p>【制药网 行业动态】近日，美国天境生物(I-Mab，NASDAQ：IMAB)宣布达成最终协议，通过全资收购Bridge Health Biotech公司，进一步巩固其在肿瘤免疫治疗领域特别是CLDN18.2靶点上的竞争优势。根据协议条款，天境生物将向Bridge Health股东支付180万美元的首付款，并在2027年前完成总计120万美元的非或有付款(assured payments)。此外，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071811115497aa94a3&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2025年全球医药行业收购活动活跃，又一家跨国药企发起“补强型并购“！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2025年全球医药行业收购活动活跃，又一家跨国药企发起“补强型并购“！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-18 11:08 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071811115497aa94a3&s=b><strong>制药网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【制药网 行业动态】近日，美国天境生物(I-Mab，NASDAQ：IMAB)宣布达成最终协议，通过全资收购Bridge Health Biotech公司，进一步巩固其在肿瘤免疫治疗领域特别是CLDN18.2靶点上的竞争优势。根据协议条款，天境生物将向Bridge Health股东支付180万美元的首付款，并在2027年前完成总计120万美元的非或有付款(assured payments)。此外，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071811115497aa94a3&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1023059063.AUD","symbol_name":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071811115497aa94a3&s=b","article_id":"2552456377","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071811115497aa94a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2552456377","pubTimestamp":1752808126,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"整个交易，预计将于2025年第三季度完成。实际上，天境生物收购Bridge Health的案例也是全球医药行业并购活动愈加活跃的体现。2025年，全球医药行业的大型并购活动频繁，且呈现出创新靶点争夺、技术平台整合与区域市场渗透三大趋势。收购完成后，礼新医药将成为中国生物制药全资子公司。总的来说，2025年医药并购呈现“创新驱动、本土崛起、CNS复兴”三大特点，跨国药企通过收购填补专利悬崖缺口，而中国药企则正通过整合本土Biotech加速国际化。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4534":"瑞士信贷持仓","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","MRK":"默沙东","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","01177":"中国生物制药","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU0861579265.USD":"联博低波幅策略股票基金A","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","SG9999014559.SGD":"United Income Focus Trust Dis SGD","BK4559":"巴菲特持仓","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","SBHMY":"中国生物制药ADR","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1"},"translate_title":"In 2025, the global pharmaceutical industry will be active in acquisitions, and another multinational pharmaceutical company will launch a \"reinforcement merger and acquisition\"!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":0.9,"SBHMY":0.9,"01177":0.9,"IMAB":0.9},"content_text":"【制药网 行业动态】近日，美国天境生物(I-Mab，NASDAQ：IMAB)宣布达成最终协议，通过全资收购Bridge Health Biotech公司，进一步巩固其在肿瘤免疫治疗领域特别是CLDN18.2靶点上的竞争优势。根据协议条款，天境生物将向Bridge Health股东支付180万美元的首付款，并在2027年前完成总计120万美元的非或有付款(assured payments)。此外，基于givastomig后续研发和注册进展，Bridge Health股东还有资格获得高至387.5万美元的里程碑付款。整个交易，预计将于2025年第三季度完成。值得一提的是，通过这笔交易，天境生物将获得CLDN18.2亲本抗体在双特异性和多特异性应用(包括双特异性抗体、多特异性抗体以及抗体药物偶联物ADC)的完整上游权利，并减少相关里程碑付款义务。综合来看，天境生物对Bridge Health的收购是一次典型的\"补强型并购\"。通过精准锁定关键知识产权，天境生物不仅巩固了其核心产品givastomig的竞争壁垒，也为未来的合作开发和商业拓展奠定了更有利的基础。实际上，天境生物收购Bridge Health的案例也是全球医药行业并购活动愈加活跃的体现。当前，创新靶点争夺、技术平台整合与区域市场渗透正在不断驱动企业的交易活动。2025年，全球医药行业的大型并购活动频繁，且呈现出创新靶点争夺、技术平台整合与区域市场渗透三大趋势。如6月，赛诺菲宣布将以91亿美元股权价值收购美国生物制药公司Blueprint Medicines Corp.(BPMC.US)。据悉，Blueprint目前主营治疗系统性肥大细胞增多症的靶向药物，该罕见病会导致免疫细胞异常积聚引发荨麻疹、腹痛等症状。此外，Blueprint还拥有包括多款在研免疫药物在内的丰富产品管线，并在专科医生群体中建立了稳固的临床网络。此次收购是赛诺菲罕见病和免疫学产品组合的战略性突破，不仅丰富了公司的研发管线，更将加速公司转型为全球头部免疫学企业的进程。7月初，默克公司宣布，已同意以约100亿美元的价格收购英国呼吸系统治疗公司Verona Pharma。根据声明，默克将以每股107美元的价格收购Verona的美国存托凭证(ADR)。两家公司的董事会均已批准这项交易，这笔交易将是默克近几十年来第三大收购案。此举被视为默克在旗下明星抗癌药物Keytruda面临 “专利悬崖”之际，积极拓宽营收来源、深化呼吸系统疾病布局的重要战略。Keytruda去年创造了近300亿美元的销售额，几乎占据默克总营收的一半。7月15日，中国生物制药在港交所公告称，拟以不超过9.51亿美元(折合人民币约68.22亿元)的交易对价收购礼新医药95.09%股权。剔除礼新医药于交割日的估计现金及银行存款约4.5亿美元，中国生物制药就收购事项待作出的付款净额约为5.01亿美元(折合人民币约35.94亿元)。收购完成后，礼新医药将成为中国生物制药全资子公司。礼新医药主要研发和管理团队，将连同公司双抗、ADC等技术平台一起加入中国生物制药。……总的来说，2025年医药并购呈现“创新驱动、本土崛起、CNS复兴”三大特点，跨国药企通过收购填补专利悬崖缺口，而中国药企则正通过整合本土Biotech加速国际化。未来，ADC、双抗、CNS和呼吸疾病领域预计仍将是药企并购热点。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2552456377","isCrawlerRequest":true}